BARBIERI, Elena
 Distribuzione geografica
Continente #
NA - Nord America 5.287
EU - Europa 2.435
AS - Asia 2.136
SA - Sud America 325
Continente sconosciuto - Info sul continente non disponibili 69
AF - Africa 52
OC - Oceania 10
Totale 10.314
Nazione #
US - Stati Uniti d'America 5.182
IT - Italia 629
SG - Singapore 624
CN - Cina 533
GB - Regno Unito 503
IE - Irlanda 346
HK - Hong Kong 263
BR - Brasile 239
SE - Svezia 217
VN - Vietnam 215
DE - Germania 214
BD - Bangladesh 153
FI - Finlandia 110
UA - Ucraina 106
RU - Federazione Russa 92
FR - Francia 66
CA - Canada 63
IN - India 63
TR - Turchia 51
KR - Corea 45
BG - Bulgaria 37
ID - Indonesia 35
AR - Argentina 24
NL - Olanda 21
IQ - Iraq 20
IR - Iran 18
ZA - Sudafrica 18
ES - Italia 16
JP - Giappone 15
MX - Messico 15
PL - Polonia 15
VE - Venezuela 15
AE - Emirati Arabi Uniti 12
CL - Cile 11
CO - Colombia 11
EC - Ecuador 11
MY - Malesia 11
PK - Pakistan 10
AZ - Azerbaigian 9
AU - Australia 8
HN - Honduras 7
TW - Taiwan 7
UZ - Uzbekistan 7
AT - Austria 6
BE - Belgio 6
EG - Egitto 6
JM - Giamaica 6
LT - Lituania 6
NG - Nigeria 6
PH - Filippine 6
PY - Paraguay 6
CZ - Repubblica Ceca 5
JO - Giordania 5
KE - Kenya 5
MT - Malta 5
NP - Nepal 5
TH - Thailandia 5
AL - Albania 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
MA - Marocco 4
PT - Portogallo 4
SA - Arabia Saudita 4
SI - Slovenia 4
UY - Uruguay 4
CH - Svizzera 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
IL - Israele 3
LB - Libano 3
LV - Lettonia 3
AO - Angola 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
ET - Etiopia 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GA - Gabon 1
GD - Grenada 1
HU - Ungheria 1
KZ - Kazakistan 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
Totale 10.242
Città #
Ashburn 547
Santa Clara 461
Singapore 424
Dublin 346
Fairfield 322
Southend 298
San Jose 294
Chandler 265
Hong Kong 258
Woodbridge 225
Houston 187
Jacksonville 176
Council Bluffs 172
Dearborn 168
Ann Arbor 162
Beijing 156
Chicago 141
Nyköping 131
Seattle 120
Wilmington 120
Los Angeles 108
Cambridge 107
London 88
New York 88
Hefei 82
Helsinki 79
The Dalles 70
Ho Chi Minh City 64
Dallas 58
Modena 57
Milan 48
Hanoi 46
Seoul 44
Munich 43
Rome 40
Salt Lake City 38
Columbus 37
Moscow 37
Princeton 37
Sofia 35
Buffalo 32
Eugene 32
Shanghai 31
Izmir 30
Lauterbourg 30
São Paulo 30
San Diego 28
Jakarta 27
Tampa 26
Elk Grove Village 25
Bremen 24
Orem 23
Bologna 22
Dong Ket 22
Phoenix 19
Fremont 16
Sterling 15
Atlanta 14
Lancaster 14
Naples 14
Redwood City 14
Catania 13
Toronto 13
Boardman 12
Tokyo 12
Frankfurt am Main 11
Haiphong 11
Palermo 11
Amsterdam 10
Florence 10
Turku 10
Brooklyn 9
Da Nang 9
Denver 9
Newark 9
Norwalk 9
Poplar 9
Redondo Beach 9
Brasília 8
Montreal 8
Surrey 8
Verona 8
Chennai 7
Des Moines 7
Dhaka 7
Falls Church 7
Miami 7
Rio de Janeiro 7
San Mateo 7
Tashkent 7
Turin 7
Warsaw 7
Baku 6
Bari 6
Belo Horizonte 6
Brescia 6
Cape Town 6
Detroit 6
Dulles 6
Ferrara 6
Totale 6.993
Nome #
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 512
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 447
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 441
Use of Recombinant Factor IX and Thromboelastography in a Patient With Hemophilia B Undergoing Liver Transplantation: A Case Report 431
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 402
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 367
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 365
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 362
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 355
Achievements and unmet needs in the management of advanced ovarian cancer 343
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 336
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 335
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 332
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 330
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 315
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 303
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 295
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 289
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 283
Biomarkers predicting clinical benefit: fact or fiction? 272
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 272
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 263
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 257
Timing for starting second-line therapy in recurrent ovarian cancer 256
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 252
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 251
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 249
Tumori ginecologici 247
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 219
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 216
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 211
Quantitative HER2 measurement and PI3K mutation profile in matched primary and metastatic breast cancer tissues. 201
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE 192
PREDICTIVE AND PROGNOSTIC ROLE OF P53 EXPRESSION IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY: A SINGLE INSTITUTION ANALYSIS 113
Totale 10.314
Categoria #
all - tutte 37.741
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.741


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022387 0 0 0 12 11 23 27 13 64 45 121 71
2022/20231.047 97 98 58 76 71 103 13 62 403 11 29 26
2023/2024559 24 21 40 39 71 46 49 118 21 27 44 59
2024/20251.508 17 41 35 110 308 251 86 104 161 69 132 194
2025/20263.341 186 68 206 407 689 198 414 140 271 291 206 265
2026/2027754 104 193 220 237 0 0 0 0 0 0 0 0
Totale 10.314